Bioage Labs, Stock Z Score
| BIOA Stock | 19.70 0.63 3.30% |
BioAge | Z Score |
BioAge Labs, Company Z Score Analysis
BioAge Labs,'s Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
BioAge Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for BioAge Labs, is extremely important. It helps to project a fair market value of BioAge Stock properly, considering its historical fundamentals such as Z Score. Since BioAge Labs,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAge Labs,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAge Labs,'s interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, BioAge Labs, has a Z Score of 0.0. This is 100.0% lower than that of the sector and 100.0% lower than that of the Z Score industry. The z score for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
BioAge Labs, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioAge Labs,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioAge Labs,'s managers, analysts, and investors.Environmental | Governance | Social |
BioAge Fundamentals
| Current Valuation | 539.05 M | ||||
| Shares Outstanding | 34.17 M | ||||
| Shares Owned By Insiders | 3.80 % | ||||
| Shares Owned By Institutions | 32.64 % | ||||
| Number Of Shares Shorted | 2.21 M | ||||
| Price To Earning | (0.84) X | ||||
| EBITDA | (45.81 M) | ||||
| Net Income | (63.85 M) | ||||
| Cash And Equivalents | 4.63 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 53.25 M | ||||
| Debt To Equity | 172.10 % | ||||
| Current Ratio | 1.35 X | ||||
| Book Value Per Share | (114.37) X | ||||
| Cash Flow From Operations | (37.36 M) | ||||
| Earnings Per Share | (5.40) X | ||||
| Number Of Employees | 56 | ||||
| Beta | 4.19 | ||||
| Market Capitalization | 674.12 M | ||||
| Total Asset | 25.92 M | ||||
| Retained Earnings | (181.7 M) | ||||
| Working Capital | (32.86 M) | ||||
| Current Asset | 10.84 M | ||||
| Current Liabilities | 29.68 M | ||||
| Net Asset | 25.92 M |
About BioAge Labs, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioAge Labs,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAge Labs, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioAge Labs, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioAge Labs, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioAge Labs,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioage Labs, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioage Labs, Stock:Check out BioAge Labs, Piotroski F Score and BioAge Labs, Valuation analysis. For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs,. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.40) |
The market value of BioAge Labs, is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs,'s value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs,'s market value can be influenced by many factors that don't directly affect BioAge Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.